ERCC1多态性对晚期非小细胞肺癌含铂化疗疗效与生存期的预测价值  

Predictive Value of Excision Repair Cross-complementation Group 1(ERCC1) Polymorphism on Chemotherapy Response and Survival of Advanced Non-small Cell Lung Cancer Patients Treated with Cisplatin

作　　者：王霖[1] 戴晓芳[2] 伍钢[2] 任精华[2] 陈卫红[2] 刘昭[2] 

机构地区：[1]湖北航天医院内科,湖北孝感432100 [2]华中科技大学同济医学院附属协和医院肿瘤中心,武汉430023

出　　处：《医药导报》2012年第6期720-724,共5页Herald of Medicine

摘　　要：目的探讨ERCC1第118位密码子C>T多态性对晚期非小细胞肺癌(NSCLC)一线含铂化疗疗效及生存期的预测价值。方法采用聚合酶链式反应-限制性内切酶片段长度多态性(PCR-RFLP)的方法,对101例接受铂剂为基础化疗的晚期NSCLC患者的ERCC1第118位密码子C>T的多态性进行检测,分析其与化疗反应率及生存期的相关性。结果 NSCLC患者ERCC1第118位密码子多态性分布与患者性别、年龄、恶性肿瘤家族史、吸烟习惯、病理类型、分期、疗效评价均无显著相关性。C/C基因型携带者的中位生存时间和一年生存率均优于C/T和T/T基因型携带者(13.7个月,10.6个月,P<0.01;67%,35%,P<0.01)。Cox多因素分析显示,性别为男性,病理类型为鳞癌,ERCC1基因型为C/T或T/T均是本组患者总体生存率低的独立预后因素(Hazard ratio=1.907,P=0.022;Hazard ratio=1.980,P=0.032;Hazard ratio=2.536,P<0.01)。结论 ERCC1第118位密码子C>T位点C等位基因是接受顺铂为基础化疗的NSCLC患者生存获益的潜在预测因素。Objective To evaluate the predictive value of excision repair cross-complementation group 1 （ ERCC1 ） codon 118 polymorphism on chemotherapy response and survival of advanced non-small cell lung cancer （NSCLC） patients treated with cisplatin. Methods In 101 advanced NSCLC＇ patients treated with platinum-based chemotherapy, polymerase chain reaction-based restriction fragment length polymorphism （PCR-RFLP） assay was used to detect ERCC1 codon 118 C〉T polymorphism. Results We found codon 118 polymorphism was not correlated with sex, age, family history of malignant cancer, smoking, pathology type and stage, and chemotherapy response. Median survival time and one-year survival rate of C/C genotype carriers were higher than those of C/T and T/T genotype carriers （ 13.7 m vs. 10.6 m; 67% vs. 35% , both P〈 0.01 ）. Multivariate analysis of Cox proportional hazard model showed that sex （ Hazard ratio = 1. 907, P = 0. 022 ） , pathology type （Hazard ratio = 1. 980, P = 0. 032 ） and ERCC1 codon 118 polymorphism （ Hazard ratio = 2. 536, P 〈 0. 01 ） were independently associated with reduced survival. Conclusion The ERCC1 codon 118 （C 〉T） C allele can be a prediction factor for better survival of advanced NSCLC patients treated with cisplatin.

关 键 词：顺铂 ERCC1 癌 非小细胞肺 单核苷酸多态性 

分 类 号：R979.1[医药卫生—药品] R734.2[医药卫生—药学]